amivantamab and mobocertinib for egfr exon-20 disease - lung cancer video library
Published 1 year ago • 465 plays • Length 6:07Download video MP4
Download video MP3
Similar videos
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
4:41
egfr exon-20 mutation - lung cancer video library
-
3:41
testing methods to discover egfr exon-20 disease - lung cancer video library
-
3:33
emerging treatments and clinical trials for egfr exon-20 - lung cancer video library
-
4:45
amivantamab and mobocertinib: side effects and treatment timing - lung cancer
-
2:34
amivantamab 和 mobocertinib：用于对抗 egfr 外显子 20 插入突变 east asian lung cancer video library
-
5:46
lung cancer video library 2020 - patel emerging molecular targets in nsclc egfr exon 20
-
1:47
amivantamab and lazertinib in egfr met disease - 2022 program: targeted therapies forum - english
-
5:07
q&a: what is the efficacy of amivantamab and lazertinib? - targeted therapies in lung cancer 2023
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
9:15
sunvozertinib & egfr exon 20 insertion nsclc-leading developments & current questions in lung cancer
-
1:02
dr reckamp on amivantamab in egfr exon 20–mutated nsclc
-
2:44
finding clinical trials for ret disease - lung cancer video library
-
22:49
grace targeted therapies lung cancer 2021 - management of uncommon egfr mutations including exon 20
-
5:18
expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
-
2:44
grace targeted therapies lung cancer 2021 -progression on tagrisso, amivantamab or better treatment?
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2